Which benzodiazepine is most appropriate for treating insomnia in otherwise healthy adults?

Benzodiazepines Should NOT Be Used for Insomnia

Benzodiazepines are explicitly NOT recommended for the treatment of chronic insomnia disorder and should be avoided in favor of nonbenzodiazepine alternatives or non-pharmacologic therapy 1.

The Evidence Against Benzodiazepines

The 2019 VA/DoD clinical practice guidelines specifically advise against use of benzodiazepines for treatment of chronic insomnia disorder 1. This represents the highest-quality guideline evidence available and should guide clinical decision-making.

If You Must Use Medication: The Hierarchy

When pharmacotherapy is necessary (and only after cognitive behavioral therapy for insomnia [CBT-I] has been considered), the preferred agents in order are:

First-Line Pharmacologic Options:

• Low-dose doxepin (3-6 mg) - Improved insomnia severity scores and sleep parameters with no significant difference in adverse events versus placebo 1
• Nonbenzodiazepine benzodiazepine receptor agonists (BZRAs): zolpidem, zaleplon, eszopiclone - These improved sleep efficiency, sleep onset latency, sleep quality, total sleep time, and wake after sleep onset 1, 2
• Orexin receptor antagonists (suvorexant, daridorexant) - Can be used for up to 3 months or longer 2, 3

Why Nonbenzodiazepine BZRAs Over Benzodiazepines:

While both classes work on benzodiazepine receptors, the nonbenzodiazepine agents (zolpidem, eszopiclone, zaleplon) have demonstrated superior safety profiles with benefits outweighing harms, whereas traditional benzodiazepines carry significant risks without superior efficacy 1.

Critical Safety Concerns

Important FDA Warning: Even the preferred nonbenzodiazepine BZRAs carry a recent FDA safety announcement regarding serious injuries from sleep behaviors (sleepwalking, sleep driving) while not fully awake 1. These agents should be:

• Prescribed at the lowest effective dose
• Used for the shortest possible duration
• Accompanied by counseling on potential risks

The Fundamental Problem with All Benzodiazepines

Traditional benzodiazepines (temazepam, triazolam, etc.) present multiple concerns:

• Lack of clear long-term safety data raises concerns about increased risks with prolonged use 1
• Risk of cognitive impairment and memory problems 4
• Daytime drowsiness and dizziness (1.8 times more likely than placebo) 4
• Potential for tolerance and dependence 5
• No demonstrated superiority over safer alternatives 1, 2

Clinical Algorithm

1. First approach: CBT-I (superior to all pharmacotherapy in long-term outcomes) 1
2. If pharmacotherapy needed: Consider low-dose doxepin (3-6 mg) or nonbenzodiazepine BZRAs (zolpidem, eszopiclone, zaleplon)
3. Duration: Short-term use (≤4 weeks) for benzodiazepine-class drugs; up to 3 months for orexin antagonists 3
4. Avoid entirely: Traditional benzodiazepines (temazepam, triazolam, etc.) 1

Special Populations

For elderly patients or those with significant comorbidities, "as-needed" administration of nonbenzodiazepine agents may be preferable to scheduled dosing 5. However, benzodiazepines remain contraindicated regardless of age.

The 2023 European Insomnia Guideline reinforces that when benzodiazepines are used at all, they should be limited to ≤4 weeks 3, but the stronger recommendation from the VA/DoD guidelines is to avoid them entirely in favor of the alternatives listed above 1.